The Ohio State University AIDS Clinical Trials Unit (ACTU) proposes to collaborate with the Adult ACTG Central Group that has identified Robert T. Schooley, M.D. from the University of Colorado as Group Leader. We wish to participate in the discovery and development of therapies that will improve the quality and duration of life of Human Immunodeficiency Virus (HIV)-infected individuals. We have a cadre of experienced investigators from multiple disciplines including infectious diseases, virology, immunology, gene therapy, oncology, neurology, gynecology, and clinical pharmacology who have demonstrated expertise conducting single- and multi-center HIV/AIDS clinical trials and in establishing multi- disciplinary collaborations to participate in the NIAID/ACTG scientific agenda. We have the nursing, pharmacy, social work, data management and outreach personnel to recruit and screen potential patients including women and minorities, implement clinical research protocols, perform protocol required assessments, dispense investigational agents and appropriately document clinical events, meeting all data reporting requirements. We have the certified laboratory facilities to conduct or obtain virologic, immunologic and pharmacologic assays in support of ACTG clinical trials with adequate internal quality control. We have the clinical facilities including a dedicated Infectious Diseases inpatient service, a full-time outpatient clinic with an ACTU pharmacy and a General Clinical Research Center to execute protocols and provide clinical care in an integrated fashion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI025924-12
Application #
2633468
Study Section
Special Emphasis Panel (SRC (30))
Project Start
1987-09-30
Project End
1999-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
12
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Brashers, Dale E; Basinger, Erin D; Rintamaki, Lance S et al. (2017) Taking Control: The Efficacy and Durability of a Peer-Led Uncertainty Management Intervention for People Recently Diagnosed With HIV. Health Commun 32:11-21
Peterson, Jennifer L; Rintamaki, Lance S; Brashers, Dale E et al. (2012) The forms and functions of peer social support for people living with HIV. J Assoc Nurses AIDS Care 23:294-305
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Raboud, Janet M; Diong, Christina; Carr, Andrew et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11:39-50
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sax, Paul E; Tierney, Camlin; Collier, Ann C et al. (2009) Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361:2230-40
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Collier, Ann C; Tierney, Camlin; Downey, Gerald F et al. (2008) Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clin Trials 9:91-102
Demeter, Lisa M; DeGruttola, Victor; Lustgarten, Stephanie et al. (2008) Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 9:11-25

Showing the most recent 10 out of 97 publications